209 related articles for article (PubMed ID: 37377974)
21. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
22. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
Wolf A; Agnihotri S; Micallef J; Mukherjee J; Sabha N; Cairns R; Hawkins C; Guha A
J Exp Med; 2011 Feb; 208(2):313-26. PubMed ID: 21242296
[TBL] [Abstract][Full Text] [Related]
23. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein.
Huang M; Xiong H; Luo D; Xu B; Liu H
Exp Cell Res; 2020 Mar; 388(2):111876. PubMed ID: 31991125
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
25. A non-metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11-mediated CD133 stability.
Wang J; Shao F; Yang Y; Wang W; Yang X; Li R; Cheng H; Sun S; Feng X; Gao Y; He J; Lu Z
Cancer Commun (Lond); 2022 Oct; 42(10):1008-1027. PubMed ID: 35975322
[TBL] [Abstract][Full Text] [Related]
26. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
27. Resibufogenin suppresses tumor growth and Warburg effect through regulating miR-143-3p/HK2 axis in breast cancer.
Guo Y; Liang F; Zhao F; Zhao J
Mol Cell Biochem; 2020 Mar; 466(1-2):103-115. PubMed ID: 32006291
[TBL] [Abstract][Full Text] [Related]
28. STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2.
Zhang L; Jiang C; Zhong Y; Sun K; Jing H; Song J; Xie J; Zhou Y; Tian M; Zhang C; Sun X; Wang S; Cheng X; Zhang Y; Wei W; Li X; Fu B; Feng P; Wu B; Shu HB; Zhang J
Nat Cell Biol; 2023 Aug; 25(8):1208-1222. PubMed ID: 37443289
[TBL] [Abstract][Full Text] [Related]
29. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription.
Wang Y; Yun Y; Wu B; Wen L; Wen M; Yang H; Zhao L; Liu W; Huang S; Wen N; Li Y
Oncotarget; 2016 Jul; 7(30):47985-47997. PubMed ID: 27351131
[TBL] [Abstract][Full Text] [Related]
30. Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
Peng M; Li H; Cao H; Huang Y; Yu W; Shen C; Gu J
J Gastroenterol; 2023 Sep; 58(9):908-924. PubMed ID: 37433897
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
[TBL] [Abstract][Full Text] [Related]
32. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
33. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
[TBL] [Abstract][Full Text] [Related]
34. PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2.
Du W; Liu N; Zhang Y; Liu X; Yang Y; Chen W; He Y
Biochem Cell Biol; 2020 Jun; 98(3):386-395. PubMed ID: 31742425
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
[TBL] [Abstract][Full Text] [Related]
36. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
37. TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer.
Dong X; Dai H; Lin Y; Sheng X; Li Y; Wang Y; Zhang X; Jiang S; Yin W; Lu J
J Transl Med; 2023 Jun; 21(1):400. PubMed ID: 37340461
[TBL] [Abstract][Full Text] [Related]
38. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme.
Wolf A; Agnihotri S; Munoz D; Guha A
Neurobiol Dis; 2011 Oct; 44(1):84-91. PubMed ID: 21726646
[TBL] [Abstract][Full Text] [Related]
39. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
[TBL] [Abstract][Full Text] [Related]
40. AKT2 phosphorylation of hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via NF-κB, HIF1α, MMP2, and MMP9 upregulation.
Li H; Lu S; Chen Y; Zheng L; Chen L; Ding H; Ding J; Lou D; Liu F; Zheng B
Cell Signal; 2019 Jun; 58():99-110. PubMed ID: 30877036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
